Document is current
Any future updates will be listed below
-
Authors
McMullan, Christel
Haroon, Shamil
Turner, Grace
Aiyegbusi, Olalekan Lee
Hughes, Sarah E.
Flanagan, Sarah
Subramanian, Anuradhaa
Nirantharakumar, Krish
Davies, Elin Haf
Frost, Chris
Jackson, Louise
Guan, Naijie
Alder, Yvonne
Chong, Amy
Buckland, Lewis
Jeyes, Felicity
Stanton, David
Calvert, Melanie
-
Funding
Funding for this research was provided by:
National Institute for Health and Care Research (COV-LT-0013)
- License Information
-
More Information
Article History
Received: 22 May 2024
Accepted: 27 March 2025
First Online: 25 April 2025
Competing interests
: CM receives funding from the NIHR Surgical Reconstruction and Microbiology Research Centre, the NIHR BTRU in Precision Transplant and Cellular Therapeutics, Innovate UK and Anthony Nolan, and has received personal fees from Aparito outside the submitted work.SH receives funding from the National Institute for Health and Care Research (NIHR) and UK Research and Innovation (UKRI).GMT receives funding from the National Institute for Health and Care Research (NIHR) and UK Research and Innovation (UKRI).SEH receives funding from the NIHR ARC, West Midlands, NIHR BTRU in Precision Transplant and Cellular Therapeutics at the University of Birmingham and Anthony Nolan. SEH declares personal fees from Cochlear and Aparito outside the submitted work. OLA declares personal fees from Gilead Sciences, Merck and GlaxoSmithKline outside the submitted work and receives funding from the NIHR Birmingham Biomedical Research Centre, NIHR Applied Research Collaboration (ARC), West Midlands, NIHR Blood and Transplant Research Unit (BTRU) in Precision Transplant and Cellular Therapeutics at the University of Birmingham and University Hospitals Birmingham NHS Foundation, Innovate UK (part of UKRI), Gilead Sciences, Merck, Anthony Nolan and Sarcoma UK.AS has no declarations during the study period; after the study was completed, she has left the University of Birmingham and taken a post in AstraZeneca.MC received personal fees from Astellas, Aparito, CIS Oncology, Takeda, Merck, Daiichi Sankyo, Glaukos, GSK and the Patient-Centered Outcomes Research Institute outside the submitted work. In addition, a family member owns shares in GSK. M.C. receives funding from the NIHR Birmingham Biomedical Research Centre, NIHR Surgical Reconstruction and Microbiology Research Centre, NIHR BTRU in Precision Transplant and Cellular Therapeutics, and NIHR ARC West Midlands at the University of Birmingham and University Hospitals Birmingham NHS Foundation Trust, Health Data Research UK, Innovate UK (part of UKRI), Macmillan Cancer Support, European Regional Development Fund—Demand Hub, SPINE UK, UKRI, UCB Pharma, GSK, Anthony Nolan and Gilead Sciences. All other authors declared no conflict of interest.
